
Jupiter Neurosciences, Inc.
$0.25
-0.0040 (-1.57%)
Latest News
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
Feb 23, 2026 09:30 AM
Jupiter Neurosciences Expands Nugevia(TM) Addressable Market with Focus on GLP-1 Users
Jan 28, 2026 06:00 AM
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
Jan 27, 2026 10:45 AM
Join Jupiter Neurosciences' Exclusive Live Investor Webinar and Q&A Session on January 6
Dec 23, 2025 08:00 AM
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
Dec 03, 2025 08:00 AM
Jupiter Neurosciences to Participate in NobleCon21
Dec 02, 2025 04:15 PM
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL(TM) in Parkinson's Disease
Nov 05, 2025 08:30 AM
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
Oct 27, 2025 08:30 AM
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia(TM) Brand Ambassador
Sep 15, 2025 08:00 AM
Jupiter Neurosciences Launches Nugevia(TM) Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
Aug 26, 2025 08:00 AM
Sign Up For JUNS Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Jupiter Neurosciences (JUNS) is a client of RedChip Companies, Inc. JUNS agreed to pay RedChip Companies, Inc. a $8,500 monthly cash fee, beginning in January 2025, for six month of investor awareness services. In May 2025, JUNS agreed to pay RedChip companies a $10,000 cash fee after its stock regained $1.00 per share. JUNS also agreed to pay RedChip a one-time $45,000 fee for a 10-day national TV ad campaign aired weekdays May 23, 2025 to June 6, 2025, and a one-time $45,000 fee for a 10-day national TV ad campaign aired weekdays in February 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.